Meksidol injection 5% 2ml amp 10 pcs


Meksidol injection 5% 2ml amp 10 pcs



Active substance:
emoxypine – 50 mg.
Sodium metabisulfite – 0.4 mg; Water for injections to 1 mL.
a colorless or slightly yellowish transparent liquid into 2 ml ampoules.
Product form:
Solution for intravenous and intramuscular administration of 50 mg / ml in ampoules colorless or light-shielding glass fracture point blue or white point and three fault marking rings (upper – yellow, medium – white, lower – red) in 2 ml. 5 ampoules in blisters. 2 blisters together with instructions for medical use in a pile of cardboard.
Acute human liver and kidneys, increased individual sensitivity to the drug. Strictly controlled clinical studies safety of the drug MEXIDOL® in children, during pregnancy and lactation was conducted.
50 mg / ml
– acute cerebral circulatory disorders;
– head injury, the effects of traumatic brain injury;
– encephalopathy;
– autonomic dystonia syndrome;
– mild cognitive disorders of atherosclerotic;
– Anxiety disorders in neurotic and neurosis-like states;
– acute myocardial infarction (the first day) in the complex therapy;
– primary open-angle glaucoma various stages composed of combination therapy;
– relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetativno– vascular disorders;
– acute intoxication antipsychotics;
– acute purulent inflammation of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) into – a part of complex therapy.
Interaction with other drugs
It enhances the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa). It reduces the toxic effects of ethanol.
with an overdose may develop drowsiness.
pharmachologic effect
Pharmacological group:
Anti-oxidant agent.
Funds for correcting violations in alcoholism, drug addiction and toxic.
It has antihypoxia, membrano, nootropic, anticonvulsant, anxiolytic action, increases resistance to stress. The preparation increases the resistance to the effects of base damaging factors to kislorodzavisimym pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, alcohol intoxication and antipsychotic drugs (neuroleptics)).
MEXIDOL® improves cerebral metabolism and cerebral blood flow, improve microcirculation and blood rheology, reduce platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets) for hemolysis. It has hypolipidemic effect, reduces total cholesterol and LDL.
Decreases enzymatic toxemia and the endogenous toxicity in acute pancreatitis.
The mechanism of action due to its Mexidol antihypoxic, antioxidative and membrane-protective effect. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein membrane reduces viscosity and increases its fluidity. Modulates the activity of membrane-associated enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, helps preserve the structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission. MEXIDOL® increases the concentration of dopamine in the brain. Causes increased compensatory activity of aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with an increase in ATP content, and activation of creatine energosinteziruyuschih mitochondrial functions, stabilization of cell membranes. MEXIDOL® normalises metabolic processes in the ischemic myocardium reduces the zone of necrosis and regeneration of electrical activity and improves myocardial contractility and coronary blood flow increases in the zone of ischemia, reperfusion syndrome reduces effects in acute coronary insufficiency. Increases anti-anginal activity nitropreparatov. MEXIDOL® promotes preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy caused by the chronic ischemia and hypoxia. It improves the functional activity of the retina and optic nerve, increasing visual acuity.
When the / m determined in plasma during the 4 hours after administration. The time to reach maximum concentration Tmax – 0,45-0,5 hours. Cmax when administered dose of 400-500 mg is 3.5-4.0 ug / ml. MEXIDOL® moves quickly from the bloodstream to organs and tissues and is rapidly eliminated from the body. The retention time of the drug (MRT) is 0.7-1.3 hours. The drug appears mainly in the urine, mainly in glyukuronokonyugirovannoy form and in small quantities unchanged.
Conditions of supply of pharmacies
on prescription.
side effects
may cause nausea and dryness of the mouth, drowsiness, allergic reactions.
special instructions
In some cases, especially in predisposed patients with bronchial asthma with hypersensitivity to sulfites may develop severe hypersensitivity reactions.
Storage conditions
stored in a cool dry place inaccessible to children at a temperature not higher than 25 ° C.
Dosing and Administration
V / m or / in (bolus or infusion). When the infusion method of administering the drug should be diluted in 0.9% sodium chloride solution.
Chip MEXIDOL® introduced slowly over 5-7 minutes, dropwise – at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
In acute cerebrovascular disorders MEXIDOL® used in the first 10-14 days – / drip -500 200 mg 2-4 times a day, then the / m, 200-250 mg 2-3 times a day for 2 weeks .
In traumatic brain injury or consequences of traumatic brain injury MEXIDOL® applied for 10-15 days / drip 200-500 mg 2-4 times a day.
In vascular encephalopathy in phase decompensation MEXIDOL® be administered in / bolus or infusion in a dose of 200-500 mg 1-2 times a day for 14 days. Then / m to 100 – 250 mg / day over the next two weeks.
For ESP preventing vascular encephalopathy introducing drug / m at a dose of 200 – 250 mg 2 times a day for 10 – 14 days.
In mild cognitive impairment in the elderly and in anxiety disorders, drug use / m at a daily dose of 100 – 300 mg / day for 14 – 30 days.
In acute myocardial infarction in the complex therapy MEXIDOL® administered intravenously or intramuscularly for 14 days, against conventional treatment of myocardial infarction comprising nitrates, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, thrombolytic agents, anticoagulant and antiplatelet agents, and symptomatic means indicated.
During the first 5 days, for maximum effect, the drug is desirably administered intravenously in the following 9 days MEXIDOL® may be administered intramuscularly.
Intravenous drug produced by drip infusion slowly (to avoid side-effects) in 0.9% sodium chloride solution or 5% dextrose (glucose) in a volume of 100-150 ml for 30-90 min. If necessary, may slow bolus of the preparation, of at least 5 minutes.
Introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg / kg body weight per day, single dose – 2-3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, single – 250 mg.
In open angle glaucoma various stages in the complex therapy MEXIDOL® intramuscularly administered 100-300 mg / day, 1-3 times a day for 14 days.
When alcohol withdrawal syndrome MEXIDOL® administered at a dose of 200-500 mg / drip or / m 2-3 times a day for 5-7 days.
In acute drug intoxication antipsychotic agents are administered in / in a dose of 200-500 mg / day for 7-14 days. In acute purulent inflammation of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) drug administered in the first day in the preoperative and postoperative. The dosage administered will depend on the type and severity of the disease, the prevalence of process variants clinical course. Cancel the drug should be done gradually only after sustained positive clinical and laboratory effects.
In acute edematous (interstitial) pancreatitis MEXIDOL® appoint 200-500 mg 3 times a day / drip (in 0.9% sodium chloride solution) and a / m. Mild necrotizing pancreatitis – 100-200 mg 3 times a day / drip (in 0.9% sodium chloride solution) and a / m. The average degree of severity – 200 mg 3 times a day / drip (in 0.9% sodium chloride solution). Severe – a pulse dosage of 800 mg on the first day at double mode of administration; Additional description of 200-500 mg 2 times a day with gradual decrease in the daily dose. It is extremely difficult for – at the initial dosage of 800 mg / day until resistant relief pankreatogennogo manifestations of shock, for stabilization of 300-500 mg 2 times a day / drip (in 0.9% sodium chloride solution), with a gradual reduction in the daily dosage.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review